Professor NADEEM QURESHI's Outputs (100)

Correction To: Quantifying the effects of risk-stratified breast cancer screening when delivered in real time as routine practice versus usual screening: the BC-Predict non-randomised controlled study (NCT04359420) (2023)
Journal Article
Gareth Evans, D., McWilliams, L., Astley, S., Brentnall, A. R., Cuzick, J., Dobrashian, R., Duffy, S. W., Gorman, L. S., Harkness, E. F., Harrison, F., Harvie, M., Jerrison, A., Machin, M., Maxwell, A. J., Howell, S. J., Wright, S. J., Payne, K., Qureshi, N., Ruane, H., Southworth, J., …French, D. P. (2023). Correction To: Quantifying the effects of risk-stratified breast cancer screening when delivered in real time as routine practice versus usual screening: the BC-Predict non-randomised controlled study (NCT04359420). British Journal of Cancer, https://doi.org/10.1038/s41416-023-02273-3

BACKGROUND: Risk stratification as a routine part of the NHS Breast Screening Programme (NHSBSP) could provide a better balance of benefits and harms. We developed BC-Predict, to offer women when invited to the NHSBSP, which collects standard risk fa... Read More about Correction To: Quantifying the effects of risk-stratified breast cancer screening when delivered in real time as routine practice versus usual screening: the BC-Predict non-randomised controlled study (NCT04359420).

The role of knowledge, primary care and community engagement to improve breast-screening access for Pakistani women in the United Kingdom: A secondary analysis of a qualitative study (2023)
Journal Article
Khattak, H. M., Woof, V. G., French, D. P., Donnelly, L. S., Ruane, H., Ulph, F., Qureshi, N., Khan, N., Evans, D. G., & Robb, K. A. (2023). The role of knowledge, primary care and community engagement to improve breast-screening access for Pakistani women in the United Kingdom: A secondary analysis of a qualitative study. Journal of Health Services Research and Policy, 28(3), 149-156. https://doi.org/10.1177/13558196231155824

Objective
Breast cancer incidence is rising among Pakistani women in the United Kingdom. However, uptake of breast screening remains low. This study aimed to improve access to breast screening for British-Pakistani women by exploring their knowledge... Read More about The role of knowledge, primary care and community engagement to improve breast-screening access for Pakistani women in the United Kingdom: A secondary analysis of a qualitative study.

Reducing Premature Coronary Artery Disease in Malaysia by Early Identification of Familial Hypercholesterolemia Using the Familial Hypercholesterolemia Case Ascertainment Tool (FAMCAT): Protocol for a Mixed Methods Evaluation Study (2023)
Journal Article
Ramli, A. S., Qureshi, N., Abdul-Hamid, H., Kamal, A., Kanchau, J. D., Shahuri, N. S., Akyea, R. K., Silva, L., Condon, L., Abdul-Razak, S., Al-Khateeb, A., Chua, Y. A., Mohamed-Yassin, M. S., Baharudin, N., Badlishah-Sham, S. F., Aziz, A. F. A., Kasim, N. A. M., Kadir, S. H. S. A., Kai, J., Leonardi-Bee, J., & Nawawi, H. (2023). Reducing Premature Coronary Artery Disease in Malaysia by Early Identification of Familial Hypercholesterolemia Using the Familial Hypercholesterolemia Case Ascertainment Tool (FAMCAT): Protocol for a Mixed Methods Evaluation Study. JMIR Research Protocols, 12, Article e47911. https://doi.org/10.2196/47911

Background: Familial hypercholesterolemia (FH) is predominantly caused by mutations in the 4 FH candidate genes (FHCGs), namely, low-density lipoprotein receptor (LDLR), apolipoprotein B-100 (APOB-100), proprotein convertase subtilisin/kexin type 9 (... Read More about Reducing Premature Coronary Artery Disease in Malaysia by Early Identification of Familial Hypercholesterolemia Using the Familial Hypercholesterolemia Case Ascertainment Tool (FAMCAT): Protocol for a Mixed Methods Evaluation Study.

Quantifying the effects of risk-stratified breast cancer screening when delivered in real time as routine practice versus usual screening: the BC-Predict non-randomised controlled study (NCT04359420) (2023)
Journal Article
Gareth Evans, D., McWilliams, L., Astley, S., Brentnall, A. R., Cuzick, J., Dobrashian, R., Duffy, S. W., Gorman, L. S., Harkness, E. F., Harrison, F., Harvie, M., Jerrison, A., Machin, M., Maxwell, A. J., Howell, S. J., Wright, S. J., Payne, K., Qureshi, N., Ruane, H., Southworth, J., …French, D. P. (2023). Quantifying the effects of risk-stratified breast cancer screening when delivered in real time as routine practice versus usual screening: the BC-Predict non-randomised controlled study (NCT04359420). British Journal of Cancer, 128, 2063-2071. https://doi.org/10.1038/s41416-023-02250-w

Background
Risk stratification as a routine part of the NHS Breast Screening Programme (NHSBSP) could provide a better balance of benefits and harms. We developed BC-Predict, to offer women when invited to the NHSBSP, which collects standard risk fa... Read More about Quantifying the effects of risk-stratified breast cancer screening when delivered in real time as routine practice versus usual screening: the BC-Predict non-randomised controlled study (NCT04359420).

Case Series of Genetically Confirmed Index Cases of Familial Hypercholesterolemia in Primary Care (2023)
Journal Article
Kamal, A., Kanchau, J. D., Shahuri, N. S., Mohamed-Yassin, M. S., Baharudin, N., Razak, S. A., Badlishah-Sham, S. F., Abdul-Hamid, H., Aziz, A. F. A., Al-Khateeb, A., Chua, Y. A., Kasim, N. A. M., Kadir, S. H. S. A., Nawawi, H., Qureshi, N., & Ramli, A. S. (2023). Case Series of Genetically Confirmed Index Cases of Familial Hypercholesterolemia in Primary Care. American Journal of Case Reports, 24, Article e939489. https://doi.org/10.12659/AJCR.939489

BACKGROUND: In Malaysia, the prevalence of genetically confirmed heterozygous familial hypercholesterolemia (FH) was reported as 1 in 427. Despite this, FH remains largely underdiagnosed and undertreated in primary care.

CASE REPORT: In this case... Read More about Case Series of Genetically Confirmed Index Cases of Familial Hypercholesterolemia in Primary Care.

How does cholesterol burden change the case for investing in familial hypercholesterolaemia? A cost-effectiveness analysis (2022)
Journal Article
Faria, R., Saramago, P., Cox, E., Weng, S., Iyen, B., Akyea, R. K., Humphries, S. E., Qureshi, N., & Woods, B. (2023). How does cholesterol burden change the case for investing in familial hypercholesterolaemia? A cost-effectiveness analysis. Atherosclerosis, 367, 40-47. https://doi.org/10.1016/j.atherosclerosis.2022.12.001

Background and aims
This study aimed to ascertain how the long-term benefits and costs of diagnosis and treatment of familial hypercholesterolaemia (FH) vary by prognostic factors and ‘cholesterol burden’, which is the effect of long-term exposure t... Read More about How does cholesterol burden change the case for investing in familial hypercholesterolaemia? A cost-effectiveness analysis.

Cardiovascular outcomes and mortality after incident ischaemic stroke in patients with a recent cancer history (2022)
Journal Article
Akyea, R. K., Iyen, B., Georgiopoulos, G., Kai, J., Qureshi, N., & Ntaios, G. (2023). Cardiovascular outcomes and mortality after incident ischaemic stroke in patients with a recent cancer history. European Journal of Internal Medicine, 109, 50-57. https://doi.org/10.1016/j.ejim.2022.12.006

Background: Up to 10% of patients with ischaemic stroke have comorbid cancer and stroke in these patients is thought to have a poor short-term prognosis. There is little known about the long-term cardiovascular morbidity and mortality outcomes after... Read More about Cardiovascular outcomes and mortality after incident ischaemic stroke in patients with a recent cancer history.

European Physician Survey Characterizing the Clinical Pathway and Treatment Patterns of Patients Post-Myocardial Infarction (2022)
Journal Article
Qureshi, N., Antoniou, S., Cornel, J. H., Schiele, F., Perrone-Filardi, P., Brachmann, J., Sidelnikov, E., Villa, G., Ferguson, S., Rowlands, C., & González-Juanatey, J. R. (2022). European Physician Survey Characterizing the Clinical Pathway and Treatment Patterns of Patients Post-Myocardial Infarction. Advances in Therapy, https://doi.org/10.1007/s12325-022-02344-6

Introduction: The 2019 European Society of Cardiology and European Atherosclerosis Society (2019 ESC/EAS) guidelines stress the importance of managing low-density lipoprotein cholesterol (LDL-C) after myocardial infarction (MI) to reduce the risk of... Read More about European Physician Survey Characterizing the Clinical Pathway and Treatment Patterns of Patients Post-Myocardial Infarction.

Electronic health record-based facilitation of familial hypercholesterolaemia detection sensitivity of different algorithms in genetically confirmed patients (2022)
Journal Article
Mohammadnia, N., Akyea, R. K., Qureshi, N., Bax, W. A., & Cornel, J. H. (2022). Electronic health record-based facilitation of familial hypercholesterolaemia detection sensitivity of different algorithms in genetically confirmed patients. European Heart Journal – Digital Health, 3(4), 578-586. https://doi.org/10.1093/ehjdh/ztac059

Aims: Familial hypercholesterolaemia (FH) is a disorder of LDL cholesterol clearance, resulting in increased risk of cardiovascular disease. Recently, we developed a Dutch Lipid Clinic Network (DLCN) criteria-based algorithm to facilitate FH detectio... Read More about Electronic health record-based facilitation of familial hypercholesterolaemia detection sensitivity of different algorithms in genetically confirmed patients.

Identifying Patients with Bicuspid Aortic Valve Disease in UK Primary Care: A Case–Control Study and Prediction Model (2022)
Journal Article
Evans, W., Akyea, R. K., Weng, S., Kai, J., & Qureshi, N. (2022). Identifying Patients with Bicuspid Aortic Valve Disease in UK Primary Care: A Case–Control Study and Prediction Model. Journal of Personalized Medicine, 12(8), Article 1290. https://doi.org/10.3390/jpm12081290

Bicuspid aortic valve disease (BAV) is the most common congenital heart condition, and early detection can improve outcomes for patients. In this case–control study, patients with a diagnosis of BAV were identified from their electronic primary-care... Read More about Identifying Patients with Bicuspid Aortic Valve Disease in UK Primary Care: A Case–Control Study and Prediction Model.

Comparison of Risk of Serious Cardiovascular Events after Hemorrhagic versus Ischemic Stroke: A Population-Based Study (2022)
Journal Article
Akyea, R. K., Georgiopoulos, G., Iyen, B., Kai, J., Qureshi, N., & Ntaios, G. (2022). Comparison of Risk of Serious Cardiovascular Events after Hemorrhagic versus Ischemic Stroke: A Population-Based Study. Thrombosis and Haemostasis, 122(11), 1921-1931. https://doi.org/10.1055/a-1873-9092

Background Patients with ischemic stroke are considered a very high risk population for subsequent cardiovascular events and guidelines recommend intensive preventive strategies. However, there is no clear recommendation that patients with hemorrhagi... Read More about Comparison of Risk of Serious Cardiovascular Events after Hemorrhagic versus Ischemic Stroke: A Population-Based Study.

Introducing genetic testing with case finding for familial hypercholesterolaemia in primary care: qualitative study of patient and health professional experience (2022)
Journal Article
Silva, L., Condon, L., Qureshi, N., Dutton, B., Weng, S., & Kai, J. (2022). Introducing genetic testing with case finding for familial hypercholesterolaemia in primary care: qualitative study of patient and health professional experience. British Journal of General Practice, 72(720), e519-e527. https://doi.org/10.3399/BJGP.2021.0558

Background: Familial hypercholesterolaemia (FH) is a common inherited condition causing elevated cholesterol, premature heart disease and early death. Although FH can be effectively treated, over 80% of people with FH remain undetected.

Aim: To e... Read More about Introducing genetic testing with case finding for familial hypercholesterolaemia in primary care: qualitative study of patient and health professional experience.

Cost-Effectiveness of Screening Algorithms for Familial Hypercholesterolaemia in Primary Care (2022)
Journal Article
Jones, M., Akyea, R. K., Payne, K., Humphries, S. E., Abdul-Hamid, H., Weng, S., & Qureshi, N. (2022). Cost-Effectiveness of Screening Algorithms for Familial Hypercholesterolaemia in Primary Care. Journal of Personalized Medicine, 12(3), Article 330. https://doi.org/10.3390/jpm12030330

Although familial hypercholesterolemia (FH) screening within primary care is considered cost-effective, which screening approach is cost-effective has not been established. This study determines the cost-effectiveness of six case-finding strategies f... Read More about Cost-Effectiveness of Screening Algorithms for Familial Hypercholesterolaemia in Primary Care.

Ethnic disparities in mortality among overweight or obese adults with newly diagnosed type 2 diabetes: a population-based cohort study (2022)
Journal Article
Iyen, B., Vinogradova, Y., Akyea, R. K., Weng, S., Qureshi, N., & Kai, J. (2022). Ethnic disparities in mortality among overweight or obese adults with newly diagnosed type 2 diabetes: a population-based cohort study. Journal of Endocrinological Investigation, 45(5), 1011-1020. https://doi.org/10.1007/s40618-021-01736-9

Purpose: Ethnic variation in risk of type 2 diabetes is well established, but its impact on mortality is less well understood. This study investigated the risk of all-cause and cardiovascular mortality associated with newly diagnosed type 2 diabetes... Read More about Ethnic disparities in mortality among overweight or obese adults with newly diagnosed type 2 diabetes: a population-based cohort study.

Understanding the barriers and enablers of pharmacogenomic testing in primary care: a qualitative systematic review with meta-aggregation synthesis (2021)
Journal Article
Qureshi, S., Latif, A., Condon, L., Akyea, R. K., Kai, J., & Qureshi, N. (2022). Understanding the barriers and enablers of pharmacogenomic testing in primary care: a qualitative systematic review with meta-aggregation synthesis. Pharmacogenomics, 23(2), 135-154. https://doi.org/10.2217/pgs-2021-0131

Introduction: Pharmacogenomic testing can indicate which drugs may have limited therapeutic action or lead to adverse effects, hence guiding rational and safe prescribing. However, in the UK and other countries, there are still significant barriers t... Read More about Understanding the barriers and enablers of pharmacogenomic testing in primary care: a qualitative systematic review with meta-aggregation synthesis.

Determining propensity for sub-optimal low-density lipoprotein cholesterol response to statins and future risk of cardiovascular disease (2021)
Journal Article
Weng, S. F., Akyea, R. K., Man, K. K., Lau, W. C. Y., Iyen, B., Blais, J. E., Chan, E. W., Siu, C. W., Qureshi, N., Wong, I. C. K., & Kai, J. (2021). Determining propensity for sub-optimal low-density lipoprotein cholesterol response to statins and future risk of cardiovascular disease. PLoS ONE, 16(12), Article e0260839. https://doi.org/10.1371/journal.pone.0260839

Background: Variability in low-density lipoprotein cholesterol (LDL-C) response to statins is underappreciated. We characterised patients by their statin response (SR), baseline risk of cardiovascular disease (CVD) and 10-year CVD outcomes.

Method... Read More about Determining propensity for sub-optimal low-density lipoprotein cholesterol response to statins and future risk of cardiovascular disease.

Statin treatment and LDL-cholesterol treatment goal attainment among individuals with familial hypercholesterolaemia in primary care (2021)
Journal Article
Iyen, B., Akyea, R. K., Weng, S., Kai, J., & Qureshi, N. (2021). Statin treatment and LDL-cholesterol treatment goal attainment among individuals with familial hypercholesterolaemia in primary care. Open Heart, 8(2), Article e001817. https://doi.org/10.1136/openhrt-2021-001817

Objectives: Guidance recommends statin treatment in Familial Hypercholesterolaemia (FH) achieve at least a 50% reduction in low-density lipoprotein cholesterol (LDL-C). We assessed statin prescribing rates and LDL-cholesterol treatment goal attainmen... Read More about Statin treatment and LDL-cholesterol treatment goal attainment among individuals with familial hypercholesterolaemia in primary care.

Comparing the performance of the novel FAMCAT algorithms and established case-finding criteria for familial hypercholesterolaemia in primary care (2021)
Journal Article
Qureshi, N., Akyea, R. K., Dutton, B., Leonardi-Bee, J., Humphries, S. E., Weng, S., & Kai, J. (2021). Comparing the performance of the novel FAMCAT algorithms and established case-finding criteria for familial hypercholesterolaemia in primary care. Open Heart, 8(2), Article e001752. https://doi.org/10.1136/openhrt-2021-001752

Objective Familial hypercholesterolaemia (FH) is a common inherited disorder causing premature coronary heart disease (CHD) and death. We have developed the novel Familial Hypercholesterolaemia Case Ascertainment Tool (FAMCAT 1) case-finding algorith... Read More about Comparing the performance of the novel FAMCAT algorithms and established case-finding criteria for familial hypercholesterolaemia in primary care.

Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease (2021)
Journal Article
Hussein, N., Henneman, L., Kai, J., & Qureshi, N. (2021). Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease. Cochrane Database of Systematic Reviews, 2021(10), Article CCD010849. https://doi.org/10.1002/14651858.cd010849.pub4

Background: Globally, about 6% of children are born with a serious birth defect of genetic or partially genetic origin. Carrier screening or testing is one way to identify couples at increased risk of having a child with an autosomal recessive condit... Read More about Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease.

Strategies for screening for familial hypercholesterolaemia in primary care and other community settings (2021)
Journal Article
Qureshi, N., Da Silva, M. L. R., Abdul-Hamid, H., Weng, S. F., Kai, J., & Leonardi-Bee, J. (2021). Strategies for screening for familial hypercholesterolaemia in primary care and other community settings. Cochrane Database of Systematic Reviews, 2021(10), Article CD012985. https://doi.org/10.1002/14651858.cd012985.pub2

Background: Familial hypercholesterolaemia is a common inherited condition that is associated with premature cardiovascular disease. The increased cardiovascular morbidity and mortality, resulting from high levels of cholesterol since birth, can be p... Read More about Strategies for screening for familial hypercholesterolaemia in primary care and other community settings.